Skip to main content

Table 1 Clinical trial schedule

From: Effect of dexamethasone in patients with ARDS and COVID-19 (REMED trial)—study protocol for a prospective, multi-centre, open-label, parallel-group, randomized controlled trial

  1. 1hCG from a peripheral blood sample in women of childbearing potential; if statim hCG is not available, perform urine pregnancy testing
  2. 2Age, sex, race or ethnic group and BMI
  3. 3Allergies, comorbidities, and Charlson Comorbidity Index (CCI) and chronic medication
  4. 4Temperature, blood pressure, heart rate and respiratory rate
  5. 5Blood count (RBC, WBC, haematocrit, lymphocyte count, platelets), coagulation profile, renal and liver functions (BUN, creatinine, bilirubin, AST, ALT), d-dimer, LDH, troponin, pH, blood gases, sodium, potassium, chloride and glycaemia (other laboratory tests and imaging methods are left at the discretion of each centre)
  6. 6Counted using the worst values in the first 24 h of ICU stay
  7. 7D1, CRP, ferritin; D2, CRP; COV-HI is defined as CRP ≥ 150 mg/L or doubling within 24 h from greater than 50 mg/L, or ferritin ≥ 1500 μg/L [11, 15, 16]
  8. 8CRP (other markers, e.g. procalcitonine, presepsin, interleukin-6 at the discretion of each centre)
  9. #End of trial visit (or phone call)